http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108822216-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate | 2018-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108822216-B |
| titleOfInvention | Carry the Chimeric antigen receptor and its application of truncation or not truncated nature cell toxin receptor signal structure |
| abstract | The present invention discloses a kind of Chimeric antigen receptor (CAR), comprising: antigen-binding domains (scfv) and signal transduction structural domain, wherein signal transduction structural domain includes the first conducting structure domain and the second conducting structure domain, antigen-binding domains of connecting between the first conducting structure domain and the second conducting structure domain.It is extremely low that cytokine levels are secreted when CAR structure disclosed by the invention is by antigenic stimulus, can guarantee that clinical application safety, i.e. clinical application safety are higher well；And exo-antigen positive tumor cell killing ability is stronger, anti-tumor activity is more preferable. |
| priorityDate | 2018-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 331.